Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) was founded in 2001 and is headquartered in New York City, New York, USA, with 193 full-time employees. It is a clinical-stage biopharmaceutical company that develops cancer in Greater China. And treatment of degenerative diseases.
Cellular Biomedicine Group (CBMG):
Cellular Biomedicine Group is a clinical research-based biopharmaceutical company dedicated to the development of immune cell therapy products for the treatment of cancer and stem cell therapy products for the treatment of degenerative diseases.
Sibiman Biotechnology Group develops cell therapies with independent intellectual property rights for the treatment of cancer and degenerative diseases. We use the products produced in the proven GMP workshop to carry out tumor immunology and stem cell clinical trials in China. Our GMP workshop in China covers 12 independent cell production lines, all of which are designed and managed in accordance with Chinese and American GMP standards.
Sibiman has two main cell technology platforms:
- A pan-tumor immune cell therapy platform using chimeric antigen receptor T cells (CAR-T) and genetically engineered T cell receptor T cells (TCR-T) and tumor infiltrating lymphocytes (TIL);
- Human adipose tissue-derived mesenchymal progenitor cells (haMPC) used to treat joints and autoimmune diseases. The company’s research and production facilities are mainly in China.
Cellular Biomedicine Group has two main cell technology platforms: stem cell platform and cancer immune cell platform
Cellular Biomedicine Group’s unique adult adipose tissue-derived stem cell and immune cell therapy product line enables it to prepare a variety of cell combination preparations when facing specific medical conditions and diseases, or apply a single species in a specific treatment plan Cell therapy. Cellular Biomedicine Group’s production facilities are certified to comply with international standards such as NSF/ANSI 49, ISO-14644 (or equivalent), ANSI/NCSL Z-540-1 and 10CFR21, and CNAS L0221 standards. On the basis of the standard plan, the company improved the processes and procedures with intellectual property rights to produce our cell series products, including:
- Storage procedures to ensure cell preservation and viability;
- DNA identification for stem cell traceability supervision;
- Biological safety testing conducted in an independent certified laboratory.
The technology of Sibiman Biotechnology Group’s cell platform is not only derived from internal development, but also through acquisition, licensing and cooperation with other companies.
Cellular Biomedicine Group’s CAR-T products include: 1) CD20 for anti-tumor activities; 2) CD22, a surface manufacturing factor, which is highly expressed in B-cell malignancies of hairy cell leukemia; 3) B-cell mature antigen therapy Treat patients with refractory multiple myeloma.
Sibyman Biotechnology Group also develops NKG2D CAR therapy for NK cell signaling; alpha-fetoprotein TCR-T for hepatocellular carcinoma; tumor infiltrating lymphocyte therapy for immunogenic cancer; knee osteoarthritis treatment, including AlloJoin therapy, which is undergoing phase I clinical trials, and Re-Join, which has completed phase IIb clinical trials.
In addition, Cellular Biomedicine Group is also engaged in biopharmaceutical business, including R&D, technical support, technical service and technology transfer activities in the field of biomedical technology; manufacturing of non-food, pharmaceutical peptides and medical devices; and wholesale of cosmetics, sanitary products and biological preparations.
Sibiman Biotechnology Group and Novartis Pharmaceuticals signed a strategic licensing and cooperation agreement to produce and supply their CAR-T cell therapy Kymriah in China.